Home › Chronic Inflammatory Demyelinating Polyradiculoneuropathy › New York
Chronic Inflammatory Demyelinating Polyradiculoneuropathy clinical trials in New York
8 studies for Chronic Inflammatory Demyelinating Polyradiculoneuropathy are looking for participants at sites in New York.
Cities in New York
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Site Number - 1605, New York
- Site Number - 1627, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT07032662Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- South Shore Neurologic Associates - Patchogue, Patchogue
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05327114A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Dent Neurologic Institute - Amherst- Site Number : 8400039, Amherst
- Hospital for Special Surgery - Site Number : 8400041, New York
- Columbia University Irving Medical Center- Site Number : 8400003, New York
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06290141A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
- TG Therapeutics Investigational Trial Site, New York
- TG Therapeutics Investigational Trial Site, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06680037A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- GC2402 Study Site 110, New York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT07540221A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
- Clinical Study Site, New York
- Clinical Study Site, New York
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 2, 2026 · NCT06858579A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
- Columbia University Irving Medical Center, New York
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Aug 14, 2026 · NCT07304154A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- NYU Langone Health, New York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jan 20, 2026 · NCT06747351From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.